Thermo Fisher Scientific Extends Reach in Pharma, Biotech with PPD Acquisition - IDEX Health & ScienceIDEX Health & Science

    Disclaimer:

    The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.

    Thermo Fisher Scientific Extends Reach in Pharma, Biotech with PPD Acquisition

    Article obtained from Photonics RSS Feed.

    Thermo Fisher Scientific is acquiring PPD Inc., a provider of clinical research services to the pharma and biotech industry. The companies’ boards of directors approved an acquisition agreement worth $17.4 billion and $47.50 per share, as well as Thermo Fisher’s assumption of approximately $3.5 billion of net debt. PPD will become part of Thermo Fisher’s laboratory products and services segment.

    In a press release, Thermo Fisher said the acquisition provides it with a drug development platform, patient recruitment capabilities, and laboratory services, supporting its capabilities in pharma and biotech.

    The transaction is expected to close by the end of 2021.

    READ MORE
    Apr, 15 2021 |

    IDEX Health & Science is the global authority in fluidics and optics, bringing to life advanced optofluidic technologies with our products, people, and engineering expertise. Intelligent solutions for life.